Apr 6, 2021

Interim Update: Launch of the Industry's First Psychedelics Genetic Test Kit

Subscribe to Excellence
Welcome aboard! Your submission has been received and you are now a member of the MedicalGold.ca community.
Oops! Something went wrong while submitting the form. Please check the format of your entry.

This morning, Entheon Biomedical (CSE:ENBI, OTC:ENTBF) announced the launch of the industry's first Psychedelics Genetic Test Kit, developed by wholly-owned subsidiary, HaluGen Life Sciences Inc., and that it is now available for sale within Canada.

Entheon Biomedical Corp. Launches HaluGen's Psychedelics Genetic Test

"HaluGen's psychedelic pre-screening platform and DNA testing provides genetic, personal and familial insights to better inform one's psychedelic assisted therapy experience. By obtaining DNA test results, individuals and healthcare professionals are equipped with data to improve psychedelic assisted therapy patient care and reduce side effects and risk. The first of its kind, the proprietary test kit and platform are also expected to be available for purchase in the US market within the coming months. The Company is currently pursuing various strategic partnerships with the goal of building brand awareness."

This is a big step for Entheon. The company now has a commercially available product in Canada, that will soon be available in the US. One of the biggest concerns I come across when discussing psychedelics with people is the safety of psychedelics, and potential contra-indications with pharmaceutical drugs that they may be prescribed. This is why it is so important for companies to develop better screening tools, and to have systems in place to ensure the safest and most effective psychedelic assisted therapy experiences possible.

Entheon is creating these tools and HaluGen's psychedelic pre-screening platform is a big first step.

For more information and price please click here.


Author owns Entheon Biomedical shares at the time of publishing and may choose to buy or sell at any time without notice. Author has been compensated for marketing services by Entheon Biomedical.


The work included in this article is based on current events, technical charts, company news releases, and the author’s opinions. It may contain errors, and you shouldn’t make any investment decision based solely on what you read here. This publication contains forward-looking statements, including but not limited to comments regarding predictions and projections. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. This publication is provided for informational and entertainment purposes only and is not a recommendation to buy or sell any security. Always thoroughly do your own due diligence and talk to a licensed investment adviser prior to making any investment decisions. Junior resource and biotechnology companies can easily lose 100% of their value so read company profiles on www.SEDAR.com for important risk disclosures. It’s your money and your responsibility.

Featured Content

No items found.